Insider Selling: RxSight, Inc. (NASDAQ:RXST) CFO Sells $526,900.00 in Stock

RxSight, Inc. (NASDAQ:RXST) CFO Shelley B. Thunen sold 10,000 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $52.69, for a total transaction of $526,900.00. Following the completion of the sale, the chief financial officer now directly owns 13,938 shares of the company’s stock, valued at approximately $734,393.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

RxSight Price Performance

Shares of NASDAQ RXST opened at $61.68 on Friday. The stock has a fifty day moving average price of $52.73 and a 200 day moving average price of $42.81. The company has a market cap of $2.28 billion, a PE ratio of -43.13 and a beta of 1.21. RxSight, Inc. has a 1-year low of $18.09 and a 1-year high of $61.85.

RxSight (NASDAQ:RXST) last released its earnings results on Wednesday, February 28th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.10. The firm had revenue of $28.58 million during the quarter, compared to analyst estimates of $28.60 million. RxSight had a negative return on equity of 31.16% and a negative net margin of 54.57%. Analysts anticipate that RxSight, Inc. will post -0.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On RxSight

Hedge funds and other institutional investors have recently made changes to their positions in the business. Artisan Partners Limited Partnership lifted its position in RxSight by 17.3% during the 3rd quarter. Artisan Partners Limited Partnership now owns 2,437,765 shares of the company’s stock worth $67,989,000 after acquiring an additional 359,295 shares in the last quarter. Vanguard Group Inc. increased its stake in RxSight by 21.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,433,953 shares of the company’s stock worth $39,993,000 after buying an additional 255,150 shares during the period. Great Lakes Advisors LLC acquired a new position in shares of RxSight in the fourth quarter worth about $8,226,000. Lord Abbett & CO. LLC increased its holdings in RxSight by 13.8% during the 3rd quarter. Lord Abbett & CO. LLC now owns 1,628,320 shares of the company’s stock worth $45,414,000 after purchasing an additional 197,099 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in RxSight by 263.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 243,346 shares of the company’s stock valued at $6,787,000 after acquiring an additional 176,451 shares in the last quarter. Institutional investors and hedge funds own 78.78% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on RXST. JPMorgan Chase & Co. upped their target price on shares of RxSight from $40.00 to $62.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Oppenheimer upped their target price on shares of RxSight from $54.00 to $61.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. Needham & Company LLC reissued a “buy” rating and set a $64.00 price target on shares of RxSight in a research report on Thursday, April 11th. Finally, Stifel Nicolaus increased their price target on shares of RxSight from $54.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $49.63.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.